RyanPM, SeltzerS, HaywardNE, et al.Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: A meta-analysis. J Pediatr, 2021; 236:137–147.e13; doi: 10.1016/j.jpeds.2021.05.009
2.
RossenLM, SchoendorfKC. Measuring health disparities: Trends in racial-ethnic and socioeconomic disparities in obesity among 2- to 18-year old youth in the United States, 2001-2010. Ann Epidemiol, 2012; 22(10):698–704.
3.
HamplSE, HassinkSG, SkinnerAC, et al.Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics, 2023; 151(2):1–100.
4.
VajraveluME, ChuPY, FrankDA, et al.Projected impact of anti-obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity. Pediatr Obes, 2024; 19(4).
5.
LuY, LiuY, KrumholzHM. Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States. J Am Heart Assoc, 2022; 11(19):e025545–8.
6.
PuhlRM, LessardLM. Weight stigma in youth: Prevalence, consequences, and considerations for clinical practice. Curr Obes Rep, 2020; 9(4):402–411.
7.
VincentMA, McCabeMP. Gender differences among adolescents in family, and peer influences on body dissatisfaction, weight loss, and binge eating behaviors. J Youth Adolesc, 2000; 29(2):205–221.
8.
PostSM, PerskyS. The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight. Int J Obes, 2024; 48(7):1019–1026.
9.
KellyAS, AuerbachP, Barrientos-PerezM, et al.NN8022-4180 Trial Investigators. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med, 2020; 382(22):2117–2128.
10.
MontaniJP, SchutzY, DullooAG. Dieting and weight cycling as risk factors for cardiometabolic diseases: Who is really at risk? Obesity Reviews, 2015; 16(S1):7–18.
